Abstracts tagged "giant cell arteritis and morbidity and mortality"

Abstract Number: 1192 • 2016 ACR/ARHP Annual Meeting
Mortality and Survival of Patients Diagnosed with GCA in Bergen (Western Norway) 1972-2012
Lene K Brekke¹, Andreas P Diamantopoulos¹, Bjørg-Tilde Fevang^2,3, Jörg Aβmus⁴ and Clara G Gjesdal^3,5, ¹Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ²Dept. of Rheumatology, Haukeland University Hospital, Bergen, Norway, ³Department of Clinical Science, University of Bergen, Bergen, Norway, ⁴Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway, ⁵Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in people ³ 50 years of age and the disease is associated with potentially…
Abstract Number: 2158 • 2015 ACR/ARHP Annual Meeting
Mortality Associated with Giant Cell Arteritis from 1980 to 2011: An Analysis of the French National Death Certificate Database
Achille Aouba¹, Solange Gonzalez-Chiappe², Mireille Eb³, Claire Delmas¹, Grégoire Rey³, Alfred Mahr² and Boris Bienvenu¹, ¹Internal Medicine, Hospital Caen, Caen, France, ²Internal Medicine, Hospital Saint-Louis, Paris, France, ³Inserm-CépiDc, Hospital Bicêtre, Le Kremlin-Bicêtre, France
Background/Purpose: Data from mostly small cohorts consistently suggest that a diagnosis of giant cell arteritis (GCA) does not substantially affect survival but GCA- and GCA…
Abstract Number: 786 • 2014 ACR/ARHP Annual Meeting
The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported
Andreas P. Diamantopoulos¹, Glenn Haugeberg¹, Lisa Amundsen², Elisabeth Wigaard¹, Dag Magnar Soldal¹ and Geirmund Myklebust¹, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Hospital of Southern Norway Trust, Kristiansand, Norway
The Incidence and Mortality rates of Giant Cell Arteritis in Southern Norway are lower than Previous ReportedBackground/Purpose Giant cell arteritis (GCA) is the most common…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].